Abstract: Varenicline is a synthetic chemical substance produced from the alkaloid cytisine, used for smoking treatment, which acts as a partial agonist for a4b2 and a3b4 nicotinic cholinergic receptors and as a total agonist for a7 receptor. While there are studies regarding varenicline's non-smoking-related effects, as in treatment for drug dependence, there are no studies in the literature evaluating the long-term toxicity of varenicline through a physiological approach. Thus, the aim of this study was to evaluate possible toxicity through haematological, biochemical and anatomopathological parameters of prolonged exposure (30 days) to varenicline in rats. Three doses of varenicline were used: 0.03 (therapeutic dose for human beings), 0.1 and 0.3 mg/kg orally (gavage). Body-weight, water and food intake were measured weekly during treatment. On the 30th treatment day, blood and various organs were collected for haematological, biochemical and anatomopathological evaluations. The results show a decrease in some biochemical parameters in animals from the 0.1 and 0.3 mg/kg group, although the values are within the normal range of the species. There were no changes in the other evaluations performed. Together, these data indicate that prolonged exposure of rats to different doses of varenicline was not able to alter haematological, biochemical and anatomopathological parameters.
Smoking is a major cause of illness and premature death worldwide. It has been related to cardiovascular, respiratory and reproductive diseases, as well as several types of cancer [1] . According to the World Health Organization (WHO), in 2017, 1 billion of the world's 7.6 billion population are smokers [2] . In the USA, the prevalence rate is around 15% [3] . Currently, there are seven types of pharmacological treatments for smoking approved by the U.S. Food and Drug Administration (FDA) [4] . One of these treatments, the prescription drug varenicline, is the most efficacious monotherapy [3, 5] .
Varenicline is a synthetic chemical substance produced from the alkaloid cytisine, which acts as a partial agonist for a4b2 and a3b4 nicotinic cholinergic receptors and as a total agonist for a7 receptor [4, 6] . This substance has a higher smoking cessation rate than other methods, such as nicotine replacement (patch, nicotine gum and spray) and other medications (bupropion and cytisine) [7] [8] [9] .
As a partial agonist, varenicline acts in two ways to exert its therapeutic effect: (1) It binds to nicotinic cholinergic receptors, activating them, which leads to the release of dopamine, promoting the same effects of nicotine, but at a much lower intensity, and without the effects of abstinence (agonist effect); (2) it prevents exogenous nicotine from binding to nicotinic cholinergic receptors, blocking the reinforcing effects of its continuous use (antagonistic effect) [9] [10] [11] .
Several studies are currently underway regarding varenicline's non-smoking-related effects. Studies have shown a potential use for varenicline for treatment of dependence on drugs, such as alcohol, opioids, cocaine and amphetamine, due to its modulation in nicotinic cholinergic receptors of the nervous system and its different effects on dopaminergic activity and other neurotransmitter systems [12] . However, no studies were found in the literature evaluating possible toxicological effects of varenicline through a physiological approach. Thus, the aim of this study was to evaluate possible toxicity through haematological, biochemical and anatomopathological parameters of prolonged exposure (30 days) to varenicline in rats.
in volumes that did not exceed 1.0 mL/kg body-weight. The administration of varenicline or water occurred each morning for 30 consecutive days.
Experimental Design. The rats were divided into four groups: three experimental groups that received different doses of varenicline (0.03, 0.1 or 0.3 mg/kg) and a control group that received water by gavage daily for 30 consecutive days (n = 10 animals/group). Body-weight and water and food intake were measured weekly during treatment.
On the 30th treatment day, the rats were submitted to euthanasia by deep anaesthesia (10 mg/kg xylazine and 70 mg/kg ketamine by intraperitoneal route) to collect blood and various organs for haematological, biochemical and anatomopathological evaluation.
Haematological Evaluation. Blood was collected by cardiac puncture and then placed in a tube with the anticoagulant EDTA. Analysis was performed through the ABX VETâ automated system, HORIBA. The parameters analysed were the levels of white blood cells (WBC), red blood cells (RBC), haematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC) and platelets (PLT).
Biochemical Evaluation. Blood was collected by cardiac puncture without anticoagulant and kept at a temperature of 25°C for 30 min. for clot retraction. The material was then centrifuged at 170 g-force (Eppendorfâ-5804 R centrifuge, São Paulo, São Paulo, Brazil) for 10 min. After centrifugation, the serum was collected and stored at À80°C for further analysis. The parameters analysed were levels of albumin, alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (FAL), gamma glutamyl transpeptidase (GGT), total protein, glucose, total cholesterol, high-density lipoprotein cholesterol (HDL), triglycerides, creatinine and urea. This analysis was performed on the ChemWellâ-T equipment (Interteck, São Paulo, São Paulo, Brazil) using commercial kits of the same brand, following the manufacturer's instructions.
Anatomopathological Evaluation. After euthanasia, the kidneys, adrenal glands, heart, lungs, liver and spleen were collected. The organs were individually weighed on analytical balance for relative weight analysis, according to the formula: organ weight (g)/animal weight (g) 9 100. The organs were then fixed in 10% neutral-buffered formalin. After fixation, the tissues were embedded in paraffin and 5-lm sections were sliced and stained with haematoxylin and eosin (HE) for microscopic examination. The histopathological evaluation was based on a qualitative analysis to identify any pathological abnormalities and lesions as potential treatment-related effects.
Statistical Analyses. The data were analysed with the software GraphPad Prism 6 for Windows (GraphPad Software, Inc., San Diego, CA, USA). The Bartlett test was used to verify the homoscedasticity of the data. For the parametric data, one-way ANOVA was used, followed by the Dunnett or Tukey post-test. For the nonparametric data, the Kruskal-Wallis test was used, followed by the Dunn test. The results were expressed as the means AE S.E., and the differences among the groups were statistically significant at p < 0.05.
Results
Body-Weight Gain and Water and Food Intake Evaluation. Fig. 1 shows the results of body-weight gain and water and food intake. On the body-weight gain evaluation, the two-way ANOVA with repeated measures showed no significant differences between treatments [F(3,144) = Haematological Evaluation. Table 1 Biochemical Evaluation. Table 2 The Dunnett post-test showed a decrease in ALT (p < 0.05), FAL (p < 0.01), total protein (p < 0.05) and urea (p < 0.05) levels in rats that received 0.1 mg/kg and a decrease in FAL (p < 0.05) and urea (p < 0.05) levels of rats that received 0.3 mg/kg of varenicline when compared to the control group.
Anatomopathological Evaluation. Table 3 shows the relative weight of organs. The nonparametric analysis of variance (Kruskal-Wallis) did not show significant differences between the groups (p > 0.05) in any of the parameters analysed.
The qualitative histopathological analysis of selected organs revealed no pathological abnormalities or potential treatmentrelated effects on the experimental rats (data not shown). Fig. 2 shows representative pictures of liver and cardiac muscle samples, displaying normal features in the control group and the rats that received 0.3 mg/kg of varenicline.
Discussion
The present study used the therapeutic dose of varenicline in human beings (0.03 mg/kg) and multiples of this dose (0.1 and 0.3 mg/kg), as well as the oral route of administration (gavage). These procedures are in accordance with protocols for toxicity evaluation that recommend the use of at least three different doses and the route of administration that the individual can be exposed to under natural conditions [13] .
These protocols also suggest that body-weight gain as well as water and food intake during the experimental procedures should be parameters evaluated as a toxicity assessment [13] . The results showed that prolonged exposure to varenicline was not able to alter these parameters, indicating absence of toxicity in all doses used in this study.
There are studies showing neurological and cardiovascular toxic effects of varenicline [1, 14] . In our study, however, these toxic effects did not alter haematological, biochemical and anatomopathological parameters, thus showing the importance of this study from a toxicological aspect.
Blood cells are very sensitive for toxic compounds and they have been used as an indicator for physiological and pathological status in human beings and animals [15] . The haematological evaluation of rats treated long-term with different doses of varenicline shows no alterations in all parameters tested, which indicates that varenicline has no effects on the circulating blood cells of animals.
The biochemical analysis was performed with the purpose of investigating whether prolonged exposure to varenicline in rats could cause hepatic, lipid or renal toxicity. Varenicline is metabolized almost exclusively in the kidneys [5] ; however, the liver is the main site for exogenous substance metabolism in a biological system [15] . Therefore, the effects of varenicline on hepatic function were also evaluated. Varenicline was also assessed to determine whether it could alter lipid metabolism.
Albumin, ALT, AST, FAL, GGT and total protein were measured for the hepatic profile. The amounts of total cholesterol, HDL cholesterol and triglycerides were used as parameters for the lipid profile. For the renal profile, creatinine and urea were quantified. Blood glucose level was also evaluated. The results of biochemistry showed a decrease in ALT, AST, FAL, total protein and urea in the 0.1 mg/kg group and a decrease in AST, FAL and urea in the 0.3 mg/kg group when compared to the control group. Although the statistical analysis indicated significant differences in these parameters, these values are within the range of physiological variation of the species [16] and the reduction in the levels of these parameters lacks biological significance. In the present study, the anatomopathological evaluation of the kidneys, adrenal glands, heart, lungs, liver and spleen was performed to examine the possible macroscopic and microscopic effects of prolonged exposure to varenicline in these organs. The results showed no significant alterations in the relative weight of the studied organs, as well as in histopathological analyses of selected tissues, indicating that varenicline was not able to alter these organs in the specific conditions of this experiment.
Varenicline is a novel medication available for smoking treatment that has higher smoking cessation rates [17] and shows a potential use for treatment of drug dependence [12] . It is important that a medication does not cause toxicity to patients during treatment. Together, these results showed that prolonged exposure of rats to different doses of varenicline did not cause toxicity, as there were no changes in any of the physiological parameters tested in this study.
